Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Kaya, Eda; Yılmaz, Yusuf

doi:10.5152/tjg.2019.18045

Cited by 37 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of NAFLD varies widely; it affects approximately 25% of individuals across the globe (7,8). Its relatively high prevalence even in apparently healthy Turkish individuals underlines the importance of early recognition of MAFLD in daily clinical practice (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

Yılmaz¹

2021

Hepatology Forum

Self Cite

View full text Add to dashboard Cite

Background and Aim:The aim of the present study was to investigate the prevalence of metabolic associated fatty liver disease (MAFLD) in patients with dyspepsia. Methods:Between January 2019 and December 2019, a total of 909 consecutive patients with complaint of dyspepsia were included.Results: Their median age was 47 years. Among them, 30.3% of the patients were obese, 18.8% had type 2 diabetes mellitus, 35.1% had metabolic syndrome, 84.8% had dyslipidemia, and 23.9% had hypertension.The prevalence of MAFLD was found to be 45.5%. Among those patients with MAFLD prevalence of obesity, type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, and hypertension were 43.3%, 24.9%, 52.5%, 92.3% and 31.9%, respectively. MAFLD was significantly associated with all the metabolic comorbidities (p<0.001). The median FIB-4 score of the MAFLD patients was 0.88 [0.1-9.5]. Of note, 53 patients with hepatic steatosis did not meet the MAFLD criteria.In Conclusion, based on the results of the present study, the prevalence of MAFLD is found to be significantly high in daily clinical practice in Turkey. Early diagnosis and prevention efforts should be aimed to reduce disease progression, which highlight application of a region based implementation strategy in our country.

show abstract

Section: Introductionmentioning

confidence: 99%

The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

Yılmaz¹

2021

Hepatology Forum

Self Cite

View full text Add to dashboard Cite

show abstract

“…NAFLD exists on a spectrum from simple steatosis to NASH. [3][4][5] The severity of hepatic fibrosis plays especially a significant role in the determination of NAFLD prognosis. NAFLD patients with advanced fibrosis have an increased tendency to progress to cirrhosis, hepatocellular carcinoma, end-stage liver failure and even liver-related mortality, which underlines the importance of timely detection of advanced fibrosis.…”

mentioning

confidence: 99%

The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases

Kaya¹,

Bakır²,

Eren³

et al. 2020

Hepatology Forum

Self Cite

View full text Add to dashboard Cite

Background and Aim: Noninvasive scores are developed for the estimation of advanced fibrosis, including parameters in addition to transaminases in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to investigate the diagnostic performances of Fibrosis-4 (FIB-4) and NAFLD Fibrosis Score (NFS) in the estimation of advanced fibrosis comparing patients with normal and elevated transaminases. Material and Methods: We retrospectively analyzed the prospectively collected data of a total of 407 consecutive patients with biopsy-proven NAFLD. FIB-4 scores of <1.3 and >2.67 or <1.45 and >3.25 indicated a low and high risk for advanced fibrosis, respectively. NFS scores of <-1.455 and >0.676 were used to assess low and high risk for advanced fibrosis, respectiv. Results: FIB-4 cutoffs of <1.3 and <1.45 for low risk of advanced fibrosis had a sensitivity of 70% and 54% in patients with elevated transaminases and 70% and 52% in patients with normal transaminases, respectively. The specificities for the cutoffs of >2.67 and >3.25 were 97% and 98% in patients with elevated transaminases and 99% and 100% in patients with normal transaminases, respectively. Concerning NFS, we found similar results. Conclusion: FIB-4 and NFS showed acceptable diagnostic performance in the exclusion of advanced fibrosis in both populations with normal and elevated transaminases.

show abstract

“…NAFLD is the involvement of steatosis in liver without the other common causes of steatosis, such as alcohol, drugs, other metabolic conditions or hereditary disorders [5,6]. Although the diagnosis is confirmed radiologically, the definitive diagnosis is made histopathologically [8].…”

Section: Discussionmentioning

confidence: 99%

Can portal vein pulsatility index be used as predictive parameter with hepatic artery resistive index for liver fibrosis in nonalcoholic hepatosteatosis?

Özdaş

Kaya

2020

Acta Medica Alanya

View full text Add to dashboard Cite

Amaç: Nonalkolik yağlı karaciğer hastalığı (NAYKH); izole karaciğer yağlanması, steatohepatit hatta siroza kadar uzanan geniş bir spektrumu barındıran klinik antitedir. Hepatit ya da siroz gelişiminde hepatik arter ve portal vendeki akım değişiklikleri saptanabilir. Çalışmanın amacı nonalkolik hepatosteatozlu hastalarda steatoz evresine göre hemodinamik bulgulardaki değişikliğin anlamlı olup olmadığının araştırılmasıdır. Gereç ve Yöntem: Çalışma Şubat-Eylül 2018 tarihleri arasında Radyoloji Bölümüne batın ultrasonografi tetkiki için başvuran hastalardan bakılan B-mod ve Doppler ultrasonografik ölçümlerle yapılmıştır. Hepatik arter rezistif indeksi (HARİ) ve portal venin pulsatilite indeksi (PVPİ) değerlendirildi. Steatozu olmayan 30 hasta ve her 3 hepatosteatoz evresinden 30'ar hasta çalışmaya dahil edildi. Hastaların çalışmaya dahil edilme kriteri olarak ek hastalık öyküsünün olmamasına bakıldı. <0.05 değerler istatistiksel olarak anlamlı kabul edildi. Bulgular: Evre 3 steatozda HARİ kontrol grubu, evre 1 ve 2 steatozdan anlamlı olarak daha düşüktü (p< 0.05).. Evre 3 steatozda, portal ven çapı evre 0, evre 1, evre 2 den anlamlı (p<0.05) olarak daha yüksekti. Evre 2 steatozda, PVPİ kontrol grubu ve evre 1 steatozdan anlamlı olarak daha düşüktü (p<0.05). Kontrol ve hasta grupları ile karşılaştırıldığında hepatik arter ve portal vende anlamlı hemodinamik değişiklikler saptanmıştır. Sonuç: PVPİ, NAYKH'de parankim hasarının değerlendirilmesinde, HARİ gibi noninvaziv değerli bir yöntem olarak görülmektedir.

show abstract

Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Cited by 37 publications

References 39 publications

The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases

Can portal vein pulsatility index be used as predictive parameter with hepatic artery resistive index for liver fibrosis in nonalcoholic hepatosteatosis?

Contact Info

Product

Resources

About